U.S. markets open in 4 hours 30 minutes
  • S&P Futures

    3,455.75
    +6.50 (+0.19%)
     
  • Dow Futures

    28,339.00
    +71.00 (+0.25%)
     
  • Nasdaq Futures

    11,665.75
    +16.00 (+0.14%)
     
  • Russell 2000 Futures

    1,636.20
    +5.60 (+0.34%)
     
  • Crude Oil

    40.59
    -0.05 (-0.12%)
     
  • Gold

    1,913.70
    +9.10 (+0.48%)
     
  • Silver

    24.92
    +0.22 (+0.87%)
     
  • EUR/USD

    1.1843
    +0.0017 (+0.14%)
     
  • 10-Yr Bond

    0.8480
    0.0000 (0.00%)
     
  • Vix

    27.91
    -0.74 (-2.58%)
     
  • GBP/USD

    1.3087
    +0.0007 (+0.06%)
     
  • USD/JPY

    104.6200
    -0.2200 (-0.21%)
     
  • BTC-USD

    12,926.79
    -39.95 (-0.31%)
     
  • CMC Crypto 200

    260.83
    +4.73 (+1.85%)
     
  • FTSE 100

    5,848.96
    +63.31 (+1.09%)
     
  • Nikkei 225

    23,516.59
    +42.32 (+0.18%)
     

Protagonist Therapeutics to Participate in the Jefferies Next Generation IBD Therapeutics Virtual Summit 2020

·1 min read

NEWARK, Calif., Sept. 17, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Next Generation IBD Therapeutics Virtual Summit 2020.

Protagonist Therapeutics, Inc. (PRNewsFoto/Protagonist Therapeutics, Inc.)
Protagonist Therapeutics, Inc. (PRNewsFoto/Protagonist Therapeutics, Inc.)

Presentation details:
Date: Wednesday, September 23, 2020
Time: 8 a.m. EDT

A live and archived webcast will be available at https://wsw.com/webcast/jeff143/ptgx/1876505 and in the Investors section of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/.

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. The Company currently has three clinical-stage assets. PTG-300 is an injectable hepcidin mimetic in development for the treatment of polycythemia vera and other blood disorders. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in development for the treatment of inflammatory bowel disease, with Crohn's disease as the initial indication. The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the development of PTG-200. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in development for the treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication.

Protagonist is headquartered in Newark, California. For further information, please visit http://www.protagonist-inc.com.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-participate-in-the-jefferies-next-generation-ibd-therapeutics-virtual-summit-2020-301133581.html

SOURCE Protagonist Therapeutics, Inc.